CAPR
What one share of Capricor Therapeutics holds
Pharmaceutical Preparations
Capricor Therapeutics, Inc. is a biotechnology company focused on the development and potential commercialization of cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy (“DMD”), a rare genetic disorder characterized by progressive muscle degeneration and premature death, as well as other diseases with significant unmet medical need.
Capricor Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.47 |
|---|---|
| Capex (buildings and equipment) | $0.21 |
| Free cash flow | −$2.19 |
| Cash and investments | $0.36 |
| Book value | $4.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $2.16 | −$10.14 | $0.10 | −$7.90 | — | −$1.87 |
| 2017 | $1.00 | $0.91 | $0.01 | −$5.32 | — | $4.27 |
| 2018 | $0.57 | −$5.17 | $0.11 | −$4.82 | — | $1.47 |
| 2019 | $0.27 | −$2.06 | $0.00 | −$1.84 | — | $1.31 |
| 2020 | $0.02 | −$0.88 | $0.04 | −$0.68 | — | $1.37 |
| 2021 | $0.01 | −$0.87 | $0.05 | −$0.78 | — | $1.30 |
| 2022 | $0.10 | −$1.18 | $0.08 | $0.12 | — | $0.47 |
| 2023 | $0.94 | −$0.83 | $0.05 | −$1.00 | — | $0.73 |
| 2024 | $0.63 | −$1.15 | $0.03 | −$1.17 | — | $3.19 |
| 2025 | $0.00 | −$2.26 | $0.06 | −$1.56 | — | $5.33 |